内容紹介
A Case of Pancreatic Body Cancer with Multiple Liver Metastases Experiencing Long-Term Response by Gemcitabine plus Erlotinib Therapy
Summary
We report a case of pancreatic body cancer with multiple liver metastases whose response duration was 295 days in a Japanese phase Ⅱ trial of gemcitabine(GEM)plus erlotinib. The patient was a 64-year-old male. He visited our hospital with the main complaint of epigastralgia and weight loss in May, 2007, and was diagnosed as advanced pancreatic cancer with abdominal paraaortic lymph node metastasis and liver metastases(Stage Ⅳ)by abdominal computed tomography and percutaneous biopsy of liver metastases. Partial response(PR)was found at the end of the sixth course of GEM+erlotinib, and his serum concentration of CA19-9 remarkably decreased. PR continued for a long period until a new lesion was found at the initiation of the seventeenth course. This result suggests that GEM+erlotinib may provide long-term survival for pancreatic cancer patients with distant metastases.
要旨
gemcitabine(GEM)+erlotinib併用の国内第Ⅱ相臨床試験において,295日の長期PR期間が得られた多発性肝転移を伴う膵体部癌を経験したので報告する。症例は64歳,男性。2007年5月,上腹部痛と体重減少を主訴として来院した。腹部CT検査,経皮的肝腫瘍生検の結果,肝転移・腹部大動脈周囲リンパ節転移を伴う進行膵体部癌(Stage Ⅳb)と診断された。GEM+erlotinib投与を開始したところ,6コース終了時PRと判定され,CA19-9の著減が認められた。17コース開始時に新病変が確認されるまでの長期間,PRが継続した。GEM+erlotinib療法は膵癌遠隔転移例に対して,長期予後が期待できる治療法となり得る可能性が示唆された。
目次
Summary
We report a case of pancreatic body cancer with multiple liver metastases whose response duration was 295 days in a Japanese phase Ⅱ trial of gemcitabine(GEM)plus erlotinib. The patient was a 64-year-old male. He visited our hospital with the main complaint of epigastralgia and weight loss in May, 2007, and was diagnosed as advanced pancreatic cancer with abdominal paraaortic lymph node metastasis and liver metastases(Stage Ⅳ)by abdominal computed tomography and percutaneous biopsy of liver metastases. Partial response(PR)was found at the end of the sixth course of GEM+erlotinib, and his serum concentration of CA19-9 remarkably decreased. PR continued for a long period until a new lesion was found at the initiation of the seventeenth course. This result suggests that GEM+erlotinib may provide long-term survival for pancreatic cancer patients with distant metastases.
要旨
gemcitabine(GEM)+erlotinib併用の国内第Ⅱ相臨床試験において,295日の長期PR期間が得られた多発性肝転移を伴う膵体部癌を経験したので報告する。症例は64歳,男性。2007年5月,上腹部痛と体重減少を主訴として来院した。腹部CT検査,経皮的肝腫瘍生検の結果,肝転移・腹部大動脈周囲リンパ節転移を伴う進行膵体部癌(Stage Ⅳb)と診断された。GEM+erlotinib投与を開始したところ,6コース終了時PRと判定され,CA19-9の著減が認められた。17コース開始時に新病変が確認されるまでの長期間,PRが継続した。GEM+erlotinib療法は膵癌遠隔転移例に対して,長期予後が期待できる治療法となり得る可能性が示唆された。